Emma Newton

Ms. Emma Newton

Tulane University School of Medicine
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ENEmma Newton
Emma Newton
LMLauren Mueller
Lauren Mueller
Scout M TreadwellScout M Treadwell
Scout M Treadwell
CMCindy A. Morris
Cindy A. Morris
HMHeather L Machado
Heather L Machado
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Due to its heterogeneity and lack of hormone receptor expression, this subtype is more likely to metastasize and resist treatment attempts than are other forms of breast cancer. Due to the absence of targetable receptors, chemotherapy and breast conserving surgery have been the predominant treatment options for patients. However, resistance to chemotherapy and local recurrence of the tumors is frequent. Emerging immunotherapies have begun to change treatment plans for patients diagnosed with TNBC. In this review, we discuss the various immune pathways identified in TNBC and the role they play as targets for new potential treatment choices. Various therapeutic options that inhibit key pathways in cellular growth cycles, DNA repair mechanisms, epithelial mesenchymal transition, and immunosuppression have been shown to improve survival in patients with this disease. With promising results thus far, continued studies of immunotherapy and neoadjuvant therapy options for TNBC are likely to alter the treatment course for these diagnoses in the future.

18 May 2022 in Cureus
Verified
Journal Article
Open access
ENEmma Newton
Emma Newton
JIJoe Iwanaga
Joe Iwanaga
ADAaron S. Dumont
Aaron S. Dumont
STShane Tubbs
Shane Tubbs
Knowledge of anatomical variations can aid the clinical practitioner in avoiding iatrogenic injury during invasive procedures. Here, we present an unusual finding of the median cubital vein and its relationship with bicipital aponeurosis. This case and relevant reports from the literature are reviewed. Physicians or other health care providers who perform procedures in the cubital fossa, such as venipuncture or vascular access, should be aware of such an anatomical variation.

15 February 2021 in Cureus
Verified
Journal Article
Open access
PDF file
SLStefan Lachkar
Stefan Lachkar
JIJoe Iwanaga
Joe Iwanaga
ENEmma Newton
Emma Newton
ADAaron S. Dumont
Aaron S. Dumont
STShane Tubbs
Shane Tubbs
The azygos venous system, which comprises the azygos, hemiazygos, and accessory hemiazygos veins, assists in blood drainage into the superior vena cava (SVC) from the thoracic cage and portions of the posterior mediastinum. Routine dissection of a fresh-frozen cadaveric specimen revealed a split azygos vein. The azygos vein branched off the inferior vena cava (IVC) at the level of the second lumbar vertebra as a single trunk and then split into two tributaries after forming a venous plexus. The right side of this system drained into the SVC and, inferiorly, the collective system drained into the IVC. Variant forms in the venous system, especially the vena cavae, are prone to dilation and tortuosity, leading to an increased likelihood of injury. Knowledge of the anatomical variations of the azygos vein is important for surgeons who use an anterior approach to the spine for diverse procedures.

1 December 2021 in Morphologie
Verified
Journal Article
Closed access
ENEmma Newton
Emma Newton
JIJ. Iwanaga
J. Iwanaga
ADA.S. Dumont
A.S. Dumont
RTR.S. Tubbs
R.S. Tubbs

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
DGDarby R. Graham
Darby R. Graham
KHKelly D. Hebert
Kelly D. Hebert
ENEmma Newton
Emma Newton
AGAngelica M. Gomes
Angelica M. Gomes
FBFariba Behbod
Fariba Behbod
HMHeather L Machado
Heather L Machado
Axl is a receptor tyrosine kinase (RTK) that is activated by its ligand Gas6 and regulates proliferation, cell survival, and clearance of apoptotic cells in both normal physiology and a number of disease states. In breast cancer, Axl is overexpressed in Her2+ and triple-negative breast cancers and is associated with resistance to RTK targeted therapies. Recent studies have shown that upon kinase inhibition, the Axl intracellular domain (ICD) can translocate to the nucleus, however, the biological significance and functions for nuclear Axl are poorly understood. Furthermore, a functional role for Axl during ductal carcinoma in situ (DCIS) progression, a requisite step for invasive breast cancer, has not been established. To address whether Axl mediates localized invasion during DCIS progression, Axl was deleted in a DCIS cell line (MCF10A-DCIS.com) using a CRISPR-Cas9 approach. Deletion of Axl shows a significant decrease in progression to invasive cancer in vivo, which is accompanied by decreased proliferation, however microinvasion is unchanged as compared to wildtype. Analysis of patient samples of pure DCIS, DCIS with microinvasion, and DCIS with invasive cancer shows a significant increase in Axl expression in patients with evidence of invasion. Interestingly, there is a significant increase in nuclear Axl in all patient samples with evidence of invasion as compared to normal breast or pure DCIS, suggesting an important role for Axl-ICD in progression to invasive cancer. Soft agar assays using normal cells (MCF10A) shows that while full length Axl (Axl-FL) is sufficient to induce colonies, Axl-ICD-transduced cells do not form colonies, suggesting that Axl-ICD alone does not have oncogenic activity. However, Axl-ICD significantly increases colonies in DCIS cells, suggesting that the ICD is important in the progression of transformed cells. Ongoing studies are aimed at identifying transcriptional targets of Axl-ICD in DCIS cells. These studies will advance our understanding of how Axl mediates breast cancer progression and will have critical implications for ongoing therapeutic strategies aimed at targeting Axl. This work is supported by NIH R01CA212518 (H.L.M.) and Susan G. Komen CCR1637765 (H.L.M.). Citation Format: Darby R. Graham, Kelly D. Hebert, Emma E. Newton, Angelica M. Gomes, Fariba Behbod, Heather L. Machado. Nuclear translocation of Axl during early breast cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 861.